The economic emergence of Asia over several decades has transformed the global economy and nearly all industries. In the case of the pharmaceutical industry, deep differences in medical practice, culture, and language presented barriers which complicated regulatory integration between Asia and the West and impeded the transformative change that regulatory integration brought to other global industries. However, recent fundamental reforms in Japan and China have opened the doors to Asia’s massive pharmaceutical markets as never before. Indeed, Asia has been brought to the center of global drug development. Ascent works with emerging biopharma to prospectively integrate Asia into global drug development thus enabling rapid Asian market entry and increasing the value of licensing partnerships in the region.